share_log

Citius Pharma Analyst Ratings

Benzinga ·  Aug 10, 2023 12:02
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/10/2023 296.59% HC Wainwright & Co. → $4 Reiterates Buy → Buy
08/01/2023 296.59% HC Wainwright & Co. $6 → $4 Maintains Buy
05/30/2023 494.88% HC Wainwright & Co. → $6 Reiterates Buy → Buy
04/03/2023 494.88% HC Wainwright & Co. → $6 Reiterates → Buy
03/29/2023 494.88% HC Wainwright & Co. → $6 Reiterates → Buy
01/18/2022 494.88% HC Wainwright & Co. $4 → $6 Maintains Buy
11/30/2021 296.59% Maxim Group → $4 Initiates Coverage On → Buy
02/07/2019 197.44% HC Wainwright & Co. → $3 Assumes → Buy

What is the target price for Citius Pharma (CTXR)?

The latest price target for Citius Pharma (NASDAQ: CTXR) was reported by HC Wainwright & Co. on August 10, 2023. The analyst firm set a price target for $4.00 expecting CTXR to rise to within 12 months (a possible 296.59% upside). 5 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Citius Pharma (CTXR)?

The latest analyst rating for Citius Pharma (NASDAQ: CTXR) was provided by HC Wainwright & Co., and Citius Pharma reiterated their buy rating.

When is the next analyst rating going to be posted or updated for Citius Pharma (CTXR)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Citius Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Citius Pharma was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.

Is the Analyst Rating Citius Pharma (CTXR) correct?

While ratings are subjective and will change, the latest Citius Pharma (CTXR) rating was a reiterated with a price target of $0.00 to $4.00. The current price Citius Pharma (CTXR) is trading at is $1.01, which is within the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment